The latest issue of the top medical authority, New England Medicine, in January 2015, published a case report in which a 65-year-old male patient with bilateral lower eyelid MALT lymphoma was reported to have disappeared after radiation therapy and was followed up for 18 months without recurrence. This article also validates the international recognition of the efficacy of radiation therapy for MALT lymphoma. Radiation therapy is the traditional treatment for ocular MALT lymphoma, and patients can choose to undergo local radiation therapy within 2-4 weeks after surgery. Radiation therapy is administered at different doses depending on the location of the lesion. Regular eye examinations are required for patients during and after treatment, including the following: visual acuity, visual field, fundus, cornea, and lens. Common complications of ocular radiation therapy include: local skin damage, dry eye, inflammation of the cornea, cataract, corneal ulcer, retinal damage, and in a very small number of patients, vision cannot be preserved or even the eye is atrophied. However, with the update of radiotherapy equipment, the development of radiotherapy technology, the wide application of analog positioning technology, and the improvement of computer technology, three-dimensional conformal radiotherapy technology is now used to ensure sufficient irradiation dose to the tumor area while minimizing damage to the surrounding normal tissues. Common complications such as dry eye, keratoconjunctivitis and local skin damage can be treated with eye drops and ointments for local anti-inflammatory treatment; in case of accelerated cataract development, cataract ultrasound emulsification combined with IOL implantation is feasible; in professional radiotherapy centers, there are very few cases of serious retinal optic nerve damage, so patients do not need to worry too much.